|Articles|July 12, 2020

Evolving PrEP to Patient-Friendly Standards

How regional-based data and advancing preventive options could bolster individual HIV-risk care access.

Pre-exposure prophylaxis (PrEP) has become a fixture in HIV preventive strategy for the better part of a decade now.

What may drive its increased use and adherence among at-risk patients is a multitude of factors just now coming into play: regional and state access assistance, improved research and collaboration, and individualized options for patients.

In an interview with Contagion during the International AIDS Society (IAS) AIDS 2020 Virtual Sessions last week, Philip Peters, MD, medical officer of the California Department of Public Health, discussed how the California PrEP Assistance Program (PrEP-AP) benefitted from a previous burden: an abundance of HIV cases in regions of the west coast.

As much as he and his colleagues have created a program foundation for other public health agencies, they’ve also benefitted from the work of others.

“It could be easier trying to figure out what’s working in another scenario then figure out if it works with what we’re doing, rather than figuring it out ourselves,” he explained.

Peters also discussed how new, promising long-acting injectable PrEP options, as well as the emerging options of on-demand PrEP, could create a greater “flexibility” in HIV prevention.

“We’re definitely going to need to have more and more flexibility in our options,” he said.

Established programs like PrEP-AP, which could help facilitate information on and access to such new options, would be hugely beneficial.


Related to this article

FDA Approves Tivicay PD for Infants With HIV
The federal agency gave the nod to dolutegravir (Tivicay PD), making it the first second-generation integrase inhibitor cleared for children with HIV weighing at least 2 kg, including eligible newborns.
This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Measles Update: September 18, 2026
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
CDC Responds to Surge in Rabies Exposures
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.